Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leadership & People

Set Alert for Leadership & People

Executives On The Move: New Hires At Ipsen, Decibel Therapeutics and Reata Pharmaceuticals

Recent executive moves in the industry include new C-suite hires at Editas Medicines, Royalty Pharma and Faron Pharmaceuticals.  

Executive Changes Leadership

Blueprint’s Evolution On Its Path To Financial Sustainability

Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.

Launches Business Strategies

Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics

The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.

Companies Leadership

Executives On The Move: C-Suite Changes At ImmunoGen, Kronos Bio, Verve Therapeutics And More

Recent executive moves in the industry include new CEOs at Rentschler Biopharma, MedinCell and OncoZenge, plus C-suite changes at Hinova Pharmaceuticals and ImmunoGen.

Executive Changes Leadership

BenevolentAI Still Bullish As CEO Shields Steps Down

BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.

Artificial Intelligence Business Strategies

GSK Reorganizes Around Key R&D Areas As Lepore Exits

The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.

Executive Changes Leadership

Executives On The Move: 12 New CEOs and 10 New CFOs

Recent executive moves in the industry include new CEOs at Baxter BioPharma Solutions, Destiny Pharma and PAION, while Medicenna Therapeutics, Mirum Pharmaceuticals and Scancell, among others, get new CFOs. 

Executive Changes Leadership

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.

Commercial Executive Changes

India M&A Hourglass: Control Deals, ‘FOMO’, Monetization Calls At Family-Owned Firms

The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.

Commercial M & A

Will CEO’s New Strategy Boost Roche’s Phase III Success?

Six months after taking the reins, Thomas Schinecker has unveiled a new approach aimed at preserving Roche’s 'R&D diversity' while cutting costly Phase III failures.

Commercial Clinical Trials

Enzene CEO On Biosimilar Denosumab And Cetuximab; Medicare Negotiation Impact On US Market

CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.

Business Strategies Commercial

Dr Reddy’s MD On The Next Horizon, Owner-Managed Firms, 'Birds And Beliefs'

Dr Reddy's Laboratories' co-chairman and MD, GV Prasad, talks about his conversations with late founder Dr Anji Reddy, the company’s ‘Horizon 2’ strategy, pricing expectations for CAR-T cell therapies, the promise of the China market, how Indian owner-managed pharma firms are figuring out ways to deal with succession aspects and his new book.

Commercial Strategy
See All
UsernamePublicRestriction

Register